![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ANGES, VICAL TO COLLABORATE ON MELANOMA THERAPY
ANGES, VICAL TO COLLABORATE ON MELANOMA THERAPY
Japan-based AnGes has signed a collaboration agreement with U.S. company Vical for Allovectin-7, Vical's proprietary immunotherapeutic for malignant melanoma.
Allovectin-7 (A-7), which consists of a DNA plasmid, can induce tumor immunity, suppressing the growth of cancer.
Under the agreement terms, AnGes will support Phase III clinical trials while receiving the right to develop and market A-7 in Asia. In addition, the partners have concluded a strategic agreement under which AnGes will offer Vical $22.6 million for Phase III clinical trials.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct